TMEM161A: A Potential Drug Target and Biomarker for Adaptive Response to Oxidative Stress Protein 29

Target Name: TMEM161A

NCBI ID: G54929

TMEM161A

TMEM161A: A Potential Drug Target and Biomarker for Adaptive Response to Oxidative Stress Protein 29

Oxidative stress and its associated diseases have become a significant public health concern in recent years. Oxidative stress occurs when the body's cells and tissues are exposed to increased levels of reactive oxygen species (ROS), which can cause damage to cells and contribute to the development of various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

Adaptive response to oxidative stress is a critical mechanism that the body uses to protect itself from the harmful effects of ROS. One of the key proteins involved in this response is Adaptive Response Protein 29 (ARP29), which plays a crucial role in the regulation of cellular stress responses.

TMEM161A: A Potential Drug Target and Biomarker for ARP29

TMEM161A is a protein that is expressed in various tissues and cells in the body. Its function is highly conserved across different species, and it is highly potential as a drug target and biomarker for ARP29.

During cellular stress, TMEM161A plays a critical role in the regulation of various cellular processes, including the production and response to ROS. It functions as a negative regulator of the ARP29 protein, which is a key transcription factor involved in the regulation of cellular stress responses.

By regulating the activity of ARP29, TMEM161A helps to ensure that the body's cells are able to adapt to oxidative stress and minimize the damage caused by ROS. This is important for the prevention of various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

The Importance of TMEM161A in Cancer Prevention

TMEM161A has been shown to play a critical role in the regulation of cancer development and progression. Many studies have demonstrated that high levels of TMEM161A are associated with the development of various types of cancer, including breast, ovarian, and prostate cancer.

Additionally, TMEM161A has been shown to promote the growth and survival of cancer cells, which suggests that it may be a potential drug target for cancer treatment. By targeting TMEM161A, researchers may be able to develop new treatments for various types of cancer.

The Potential of TMEM161A as a Biomarker

TMEM161A may also be a valuable biomarker for the diagnosis and monitoring of various diseases. For example, high levels of TMEM161A have been shown to be associated with the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Additionally, TMEM161A has been shown to be involved in the regulation of various cellular processes, including cell signaling and stress responses. This suggests that it may be a useful biomarker for the detection and treatment of cellular stress-related diseases, such as fibrosis and neurofibrillary tangles.

Conclusion

TMEM161A is a protein that plays a critical role in the regulation of cellular stress responses and has been shown to be involved in the development and progression of various diseases, including cancer. Its function as a negative regulator of ARP29 makes it a potential drug target and biomarker for ARP29. Further research is needed to fully understand the role of TMEM161A in the regulation of cellular stress responses and its potential as a drug target and biomarker for various diseases.

Protein Name: Transmembrane Protein 161A

Functions: May play a role in protection against oxidative stress. Overexpression leads to reduced levels of oxidant-induced DNA damage and apoptosis

The "TMEM161A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM161A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets